Atypical depot antipsychotic
Olanzapine embonate
Brand names: ZypAdhera
Adult dose
Dose: 150–300mg deep IM every 2 weeks (or 405mg every 4 weeks); supervised
Route: Deep IM (gluteal)
Frequency: q2-4w
Clinical pearls
- Schizophrenia maintenance with poor adherence
- Mandatory 3-hour post-injection observation in registered facility (post-injection syndrome)
Contraindications
- As olanzapine
Side effects
- Post-injection syndrome (sedation/delirium for 1–3h — observe ≥3h post-dose)
- Weight gain
- Metabolic syndrome
- Sedation
- EPSE
- Hyperprolactinaemia
Interactions
- CNS depressants
- Levodopa
- Smoking cessation (raises levels)
Monitoring
- Post-dose 3h observation
- Weight
- Glucose
- Lipids
- BP
- Prolactin
Reference: BNF; Maudsley; SmPC; https://bnf.nice.org.uk/drugs/olanzapine-embonate/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Pathways
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185 / BNF